3-D DNA methylation phenotypes correlate with cytotoxicity levels in prostate and liver cancer cell models

BMC Pharmacology and Toxicology

Volumn 14, Issue , 2013, Pages

  Gertych, Arkadiusz ^a   Oh, Jin Ho ^a   Wawrowsky, Kolja A ^a   Weisenberger, Daniel J ^b   Tajbakhsh, Jian ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

3D image analysis; Chromatin distribution; DNA methylation phenotype; Epigenetic drug; High throughput cell assay; MethyLight; Repetitive element

Indexed keywords

5 METHYLCYTOSINE; AZACITIDINE; CYTOSINE; ZEBULARINE; ANTINEOPLASTIC AGENT; CYTIDINE; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; PYRIMIDIN 2 ONE BETA RIBOFURANOSIDE; PYRIMIDIN-2-ONE BETA-RIBOFURANOSIDE;

ARTICLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL DIVISION; CELL GROWTH; CELL MEDIATED CYTOTOXICITY; CELL VIABILITY; CHROMATIN; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DNA DETERMINATION; DNA METHYLATION; DNA SEQUENCE; DRUG CONCENTRATION; DRUG SENSITIVITY; EPIGENETICS; HUMAN; HUMAN CELL; IC 50; IMAGE ANALYSIS; LIVER CANCER; MALE; PHENOTYPE; PROSTATE CANCER; SCANNING ELECTRON MICROSCOPY; APOPTOSIS; CELL SURVIVAL; DRUG EFFECT; IMMUNOLOGY; LIVER TUMOR; PROSTATE TUMOR; TUMOR CELL LINE;

5-METHYLCYTOSINE; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; AZACITIDINE; CELL LINE, TUMOR; CELL SURVIVAL; CYTIDINE; DNA METHYLATION; HUMANS; LIVER NEOPLASMS; MALE; PHENOTYPE; PROSTATIC NEOPLASMS;

MLCS; MLOWN;

EID: 84879009564     PISSN: 20506511     EISSN: None     Source Type: Journal    
DOI: 10.1186/2050-6511-14-11     Document Type: Article

References (101)

1. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 2003, 33:245-254. 10.1038/ng1089, 12610534.
2. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007, 128:683-692. 10.1016/j.cell.2007.01.029, 17320506.
3. Herman JG, Baylin SB. Gene silencing in cancer is associated with promoter hypermethylation. N Engl J Med 2003, 349:2042-2054. 10.1056/NEJMra023075, 14627790.
4. Esteller M. Epigenetics in cancer. N Engl J Med 2008, 358:1148-1159. 10.1056/NEJMra072067, 18337604.
5. Costello JF, Frühwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomäki P, Lang JC, Schuller DE, Yu L, Bloomfield CD, Caligiuri MA, Yates A, Nishikawa R, Su Huang H, Petrelli NJ, Zhang X, O'Dorisio MS, Held WA, Cavenee WK, Plass C. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 2000, 24:132-138. 10.1038/72785, 10655057.
6. Ehrlich M, Gama-Sosa MA, Huang LH, Midgett RM, Kuo KC, McCune RA, Gehrke C. Amount and distribution of 5-methylcytosine in human DNA from different types of tissues of cells. Nucleic Acids Res 1982, 10:2709-2721. 10.1093/nar/10.8.2709, 320645, 7079182.
7. Gardiner-Garden M, Frommer M. CpG islands in vertebrate genomes. J Mol Biol 1987, 196:261-282. 10.1016/0022-2836(87)90689-9, 3656447.
8. Ehrlich M. DNA Hypomethylation in cancer cells. Epigenomics 2009, 1:239-259. 10.2217/epi.09.33, 2873040, 20495664.
9. Puitri EL, Robertson KD. Epigenetic mechanisms and genome stability. Clin Epigenetics 2011, 2:299-314. 10.1007/s13148-010-0017-z, 3172155,3172155, 21927626.
10. Peng JC, Karpen GH. Epigenetic regulation of heterochromatic stability. Curr Opin Genet Dev 2008, 18:204-211. 10.1016/j.gde.2008.01.021, 2814359, 18372168.
11. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983, 301:89-92. 10.1038/301089a0, 6185846.
12. Gama-Sosa MA, Slagel VA, Trewyn RW, Oxenhandler R, Kuo KC, Kuo KC, Gehrke CW, Ehrlich M. The 5-methylcytosine content of DNA from human tumors. Nucleic Acid Res 1983, 11:6883-6894. 10.1093/nar/11.19.6883, 326421, 6314264.
13. Ehrlich M. NA hypomethylation and cancer. DNA Alterations in Cancer: Genetic and Epigenetic Changes 2000, 273-291. Natick, MA: Eaton Publishing, Ehrlich M.
14. Dunn BK. Hypomethylation: one side of a larger picture. Ann N Y Acad Sci 2003, 983:28-42. 10.1111/j.1749-6632.2003.tb05960.x, 12724210.
15. Fraser P, Bickmore W. Nuclear organization of the genome and the potential for gene regulation. Nature 2007, 447:413-417. 10.1038/nature05916, 17522674.
16. Deal RB, Henikoff S. Capturing the dynamic epigenome. Genome Biol 2010, 11:218. 10.1186/gb-2010-11-10-218, 3218653, 20959022.
17. Misteli T. Higher-order genome organization in human disease. Cold Spring Harb Perspect Biol 2010, 2:a000794. 10.1101/cshperspect.a000794, 2908770, 20591991.
18. Li G, Reinberg D. Chromatin higher-order structures and gene regulation. Curr Opin Genet Dev 2011, 21:175-186. 10.1016/j.gde.2011.01.022, 3124554, 21342762.
19. Tajbakhsh J. DNA methylation topology: potential of a chromatin landmark for epigenetic drug toxicology. Epigenomics 2011, 3:761-770. 10.2217/epi.11.101, 3250213, 22126294.
20. Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006, 5:37-50. 10.1038/nrd1930, 16485345.
21. Gore SD, Jones C, Kirkpatrick P. Decitabine. Nat Rev Drug Discov 2006, 5:891-892. 10.1038/nrd2180, 17117522.
22. Issa JP, Kantarjian H. 5-azacytidine. Nat Rev Drug Discov 2005, (Suppl):S6-S7.
23. Cheng JC, Matsen CB, Gonzales FA, Ye W, Greer S, Marquez VE, Jones PA, Selker EU. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst 2003, 95:399-409. 10.1093/jnci/95.5.399, 12618505.
24. Yoo CB, Cheng JC, Jones PA. Zebularine: a new drug for epigenetic therapy. Biochem Soc Trans 2004, 32:910-912. 10.1042/BST0320910, 15506921.
25. Marquez VE, Kelley JA, Agbaria R, Ben-Kasus T, Cheng JC, Yoo CB, Jones PA. Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy. Ann N Y Acad Sci 2005, 1058:246-254. 10.1196/annals.1359.037, 16394141.
26. Herranz M, Martín-Caballero J, Fraga MF, Ruiz-Cabello J, Flores JM, Desco M, Marquez V, Esteller M. The novel DNA methylation inhibitor zebularine is effective against the development of murine T-cell lymphoma. Blood 2006, 107:1174-1177.
27. Stresemann C, Bokelmann I, Mahlknecht U, Lyko F. 5-azacytidine causes complex DNA methylation responses in myeloid leukemia. Mol Cancer Ther 2008, 7:2998-3005. 10.1158/1535-7163.MCT-08-0411, 18790780.
28. Santi DV, Norment A, Garrett CE. Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl Acad Sci USA 1984, 81:6993-6997. 10.1073/pnas.81.22.6993, 392062, 6209710.
29. Bender CM, Gonzalgo ML, Gonzales FA, Nguyen CT, Robertson KD, Jones PA. Roles of Cell Division and Gene Transcription in the Methylation of CpG Islands. Mol Cell Biol 1999, 19:6690-6698. 84656, 10490608.
30. Weisenberger DJ, Velicescu M, Cheng JC, Gonzales FA, Liang G, Jones PA. Role of the DNA Methyltransferase Variant DNMT3b3 in DNA Methylation. Mol Cancer Res 2004, 2:62-72.
31. Ghoshal K, Datta J, Majumder S, Bai S, Kutay H, Motiwala T, Jacob ST. 5-Aza-Deoxycytidine Induces Selective Degradation of DNA Methyltransferase 1 by a Proteasomal Pathway That Requires the KEN Box, Bromo-Adjacent Homology Domain, and Nuclear Localization Signal. Mol Cell Biol 2005, 25:4727-4741. 10.1128/MCB.25.11.4727-4741.2005, 1140649, 15899874.
32. Zhu WG, Hileman T, Ke Y, Wang P, Lu S, Duan W, Dai Z, Tong T, Villalona-Calero MA, Plass C, Otterson GA. 5-aza-2′-deoxycytidine activates the p53/p21Waf1/Cip1 pathway to inhibit cell proliferation. J Biol Chem 2004, 279:15161-15166. 10.1074/jbc.M311703200, 14722112.
33. Yang X, Noushmehr H, Han H, Andreu-Vieyra C, Liang G, Jones PA. Gene reactivation by 5-aza-2′-deoxycytidine-induced demethylation requires SRCAP-mediated H2A.Z insertion to establish nucleosome depleted regions. PLoS Genet 2012, 8:e1002604. 10.1371/journal.pgen.1002604, 3315468, 22479200.
34. Patra SK, Patra A, Rizzi F, Ghosh TC, Bettuzzi S. Demethylation of (Cytosine-5-C-methyl) DNA and regulation of transcription in the epigenetic pathways of cancer development. Cancer Metastasis Rev 2008, 27:315-334. 10.1007/s10555-008-9118-y, 18246412.
35. Patra SK, Bettuzzi S. Epigenetic DNA-(cytosine-5-carbon) modifications: 5-aza-2′-deoxycytidine and DNA-demethylation. Biochemistry (Mosc) 2009, 74:613-619.
36. Ammerpohl O, Martin-Subero JI, Richter J, Vater I, Siebert R. Hunting for the 5th base: Techniques for analyzing DNA methylation. Biochim Biophys Acta 2009, 1790:847-862. 10.1016/j.bbagen.2009.02.001, 19364478.
37. Laird PW. Principles and challenges of genome-wide DNA methylation analysis. Nat Rev Genet 2010, 11:191-203.
38. Fatemi M, Pao MM, Jeong S, Gal-Yam EN, Egger G, Weisenberger DJ, Jones PA. Footprinting of mammalian promoters: use of a CpG DNA methyltransferase revealing nucleosome positions at a single molecule level. Nucleic Acids Res 2005, 33:e176. 10.1093/nar/gni180, 1292996, 16314307.
39. Kelly TK, Liu Y, Lay FD, Liang G, Berman BP, Jones PA. Genome-wide mapping of nucleosome positioning and DNA methylation within individual DNA molecules. Genome Res 2012, 22:2497-2506. 10.1101/gr.143008.112, 22960375.
40. Haaf T. The effects of 5-azacytidine and 5-azadeoxycytidine on chromosome structure and function: implications for methylation-associated cellular processes. Pharmacol Ther 1995, 65:19-46. 10.1016/0163-7258(94)00053-6, 7536332.
41. De Capoa A, Menendez F, Poggesi I, Giancotti P, Grappelli C, Marotta MR, Di Leandro M, Reynaud C, Niveleau A. Cytological evidence for 5-azacytidine-induced demethylation of the heterochromatic regions of human chromosomes. Chromosome Res 1996, 4:271-276. 10.1007/BF02263676, 8817066.
42. Tajbakhsh J, Wawrowsky KA, Gertych A, Bar-Nur O, Vishnevsky E, Lindsley EH, Farkas DL. Characterization of tumor cells and stem cells by differential nuclear methylation imaging. Imaging, Manipulation, and Analysis of Biomolecules, Cells, and Tissues. Proceedings of the SPIE: 19-24 January 2008 2008, 6859F1-6859F10. San Jose, CA: SPIE Publications, Farkas DL DL, Nicolau DV, Robert C, Leif RC.
43. Gertych A, Wawrowsky KA, Lindsley E, Vishnevsky E, Farkas DL, Tajbakhsh J. Automated quantification of DNA demethylation effects in cells via 3D mapping of nuclear signatures and population homogeneity assessment. Cytometry A 2009, 75:569-583. 2763559, 19459215.
44. Gertych A, Farkas DL, Tajbakhsh J. Measuring topology of low-intensity DNA methylation sites for high-throughput assessment of epigenetic drug-induced effects in cancer cells. Exp Cell Res 2010, 316:3150-3160. 10.1016/j.yexcr.2010.08.013, 2963693, 20813111.
45. Szyf M. Epigenetics, DNA methylation, and chromatin modifying drugs. Annu Rev Pharmacol Toxicol 2009, 49:243-263. 10.1146/annurev-pharmtox-061008-103102, 18851683.
46. Tajbakhsh J, Gertych A, Farkas DL. Utilizing nuclear DNA methylation patterns in cell-based assays for epigenetic drug screening. Drug Discovery World 2010, 27-35. spring edition.
47. Tong WG, Wierda WG, Lin E, Kuang SQ, Bekele BN, Estrov Z, Wei Y, Yang H, Keating MJ, Garcia-Manero G. Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact. Epigenetics 2010, 5:499-508. 10.4161/epi.5.6.12179, 3322493, 20484983.
48. Ehrlich M. DNA hypomethylation, cancer, the immunodeficiency, centromeric region instability, facial anomalies syndrome and chromosomal rearrangements. J Nutr 2002, 132:2424S-2429S.
49. Espada J, Esteller M. Epigenetic control of nuclear architecture. Cell Mol Life Sci 2007, 64:449-457. 10.1007/s00018-007-6358-x, 2771143, 17221334.
50. Santos AP, Abranches R, Stoger E, Beven A, Viegas W, Shaw PJ. The architecture of interphase chromosomes and gene positioning are altered by changes in DNA methylation and histone acetylation. J Cell Sci 2002, 115:4597-4605. 10.1242/jcs.00160, 12415004.
51. Gilbert N, Thomson I, Boyle S, Allan J, Ramsahoye B, Bickmore WA. DNA methylation affects nuclear organization, histone modifications, and linker histone binding but not chromatin compaction. J Cell Biol 2007, 177:401-411. 10.1083/jcb.200607133, 2064831, 17485486.
52. Christman JK. 5-azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002, 21:5483-5495. 10.1038/sj.onc.1205699, 12154409.
53. Stresemann C, Brueckner B, Musch T, Stopper H, Lyko F. Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res 2006, 66:2794-2800. 10.1158/0008-5472.CAN-05-2821, 16510601.
54. Dote H, Cerna D, Burgan WE, Carter DJ, Cerra MA, Hollingshead MG, Camphausen K, Tofilon PJ. Enhancement of in vitro and in vivo tumor cell radiosensitivity by the DNA methylation inhibitor zebularine. Clin Cancer Res 2005, 11:4571-4579. 10.1158/1078-0432.CCR-05-0050, 15958643.
55. Schwarze SR, Fu VX, Desotelle JA, Kenowski ML, Jarrard DF. The identification of senescence-specific genes during the induction of senescence in prostate cancer cells. Neoplasia 2005, 7:816-823. 10.1593/neo.05250, 1501939, 16229804.
56. Ewald J, Desotelle J, Almassi N, Jarrard D. Drug-induced senescence bystander proliferation in prostate cancer cells in vitro and in vivo. Br J Cancer 2008, 98:1244-1249. 10.1038/sj.bjc.6604288, 2359629, 18349844.
57. Patra A, Deb M, Dahiya R, Patra SK. 5-Aza-2′-deoxycytidine stress response and apoptosis in prostate cancer. Clin Epigenetics 2011, 2:339-348. 10.1007/s13148-010-0019-x, 3365594, 22704346.
58. Venturelli S, Armeanu S, Pathil A, Hsieh CJ, Weiss TS, Vonthein R, Wehrmann M, Gregor M, Lauer UM, Bitzer M. Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma. Cancer 2007, 109:2132-2141. 10.1002/cncr.22652, 17407132.
59. Andersen JB, Factor VM, Marquardt JU, Raggi C, Lee YH, Seo D, Conner EA, Thorgeirsson SS. An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer. Sci Transl Med 2010, 2:54ra77. 10.1126/scitranslmed.3001338, 3077922, 20962331.
60. Heinemann L, Simpson GR, Annels NE, Vile R, Melcher A, Prestwich R, Harrington KJ, Pandha HS. The effect of cell cycle synchronization on tumor sensitivity to reovirus oncolysis. Mol Ther 2010, 18:2085-2093. 10.1038/mt.2010.189, 2997589, 20842107.
61. Whitfield ML, Zheng LX, Baldwin A, Ohta T, Hurt MM, Marzluff WF. Stem-loop binding protein, the protein that binds the 3′ end of histone mRNA, is cell cycle regulated by both translational and posttranslational mechanisms. Mol Cell Biol 2000, 20:4188-4198. 10.1128/MCB.20.12.4188-4198.2000, 85788, 10825184.
62. Wong C, Stearns T. Mammalian cells lack checkpoints for tetraploidy, aberrant centrosome number, and cytokinesis failure. BMC Cell Biol 2005, 6:6. 10.1186/1471-2121-6-6, 554097, 15713235.
63. van Engeland M, Nieland LJ, Ramaekers FC, Schutte B, Reutelingsperger CP. Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 1998, 31:1-9. 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R, 9450519.
64. Tajbakhsh J, Gertych A. Three-dimensional quantitative DNA methylation imaging for chromatin texture analysis in pharmacoepigenomics and toxicoepigenomics. Epigenomics: From Chromatin Biology to Therapeutics 2012, 273. Cambridge, UK: Cambridge University Press, Appasani K.
65. Weisenberger DJ, Campan M, Long TI, Kim M, Woods C, Fiala E, Ehrlich M, Laird PW. Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res 2005, 33:6823-6836. 10.1093/nar/gki987, 1301596, 16326863.
66. Cowell IG, Aucott R, Mahadevaiah SK, Burgoyne PS, Huskisson N, Bongiorni S, Prantera G, Fanti L, Pimpinelli S, Wu R, Gilbert DM, Shi W, Fundele R, Morrison H, Jeppesen P, Singh PB. Heterochromatin, HP1 and methylation at lysine 9 of histone H3 in animals. Chromosoma 2002, 111:22-36. 10.1007/s00412-002-0182-8, 12068920.
67. Lachner M, O'Carroll D, Rea S, Mechtler K, Jenuwein T. Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. Nature 2001, 410:116-120. 10.1038/35065132, 11242053.
68. Peng JC, Karpen GH. Heterochromatic genome stability requires regulators of histone H3 K9 methylation. PLoS Genet 2009, 5:e1000435. 10.1371/journal.pgen.1000435, 2654965, 19325889.
69. Shvachko LP. Alterations of constitutive pericentromeric heterochromatin in lymphocytes of cancer patients and lymphocytes exposed to 5-azacytidine is associated with hypomethylation. Exp Oncol 2008, 30:230-234.
70. Chiam K, Centenera MM, Butler LM, Tilley WD, Bianco-Miotto T. GSTP1 DNA methylation and expression status is indicative of 5-aza-2′-deoxycytidine efficacy in human prostate cancer cells. PLoS One 2011, 6:e25634. 10.1371/journal.pone.0025634, 3182253, 21980513.
71. Chen M, Shabashvili D, Nawab A, Yang SX, Dyer LM, Brown KD, Hollingshead M, Hunter KW, Kaye FJ, Hochwald SN, Marquez VE, Steeg P, Zajac-Kaye M. DNA methyltransferase inhibitor, zebularine, delays tumor growth and induces apoptosis in a genetically engineered mouse model of breast cancer. Mol Cancer Ther 2012, 11:370-382. 10.1158/1535-7163.MCT-11-0458, 22203734.
72. Lang P, Yeow K, Nichols A, Scheer A. Cellular imaging in drug discovery. Nat Rev Drug Discov 2006, 5:343-356. 10.1038/nrd2008, 16582878.
73. Cheng JC, Weisenberger DJ, Gonzales FA, Liang G, Xu GL, Hu YG, Marquez VE, Jones PA. Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol 2004, 24:1270-1278. 10.1128/MCB.24.3.1270-1278.2004, 321446, 14729971.
74. Scott SA, Lakshimikuttysamma A, Sheridan DP, Sanche SE, Geyer CR, Hu YG, Marquez VE, Jones PA. Zebularine inhibits human acute myeloid leukemia cell growth in vitro in association with p15INK4B demethylation and reexpression. Exp Hematol 2007, 35:263-273. 10.1016/j.exphem.2006.10.005, 17258075.
75. Billam M, Sobolewski MD, Davidson NE. Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells. Breast Cancer Res Treat 2010, 120:581-592. 10.1007/s10549-009-0420-3, 19459041.
76. van Bemmel DM, Brank AS, Eritja R, Marquez VE, Christman JK. DNA (Cytosine-C5) methyltransferase inhibition by oligodeoxyribonucleotides containing 2-(1H)-pyrimidinone (zebularine aglycon) at the enzymatic target site. Biochem Pharmacol 2009, 78:633-641. 10.1016/j.bcp.2009.05.017, 2756644, 19467223.
77. Champion C, Guianvarc'h D, Sénamaud-Beaufort C, Jurkowska RZ, Jeltsch A, Ponger L, Arimondo PB, Guieysse-Peugeot AL. Mechanistic insights on the inhibition of c5 DNA methyltransferases by zebularine. PLoS One 2010, 5:e12388. 10.1371/journal.pone.0012388, 2927531, 20808780.
78. Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors 5-azacytidine and decitabine. Int J Cancer 2008, 123:8-13. 10.1002/ijc.23607, 18425818.
79. Huang J, Plass C, Gerhauser C. Cancer chemoprevention by targeting the epigenome. Curr Drug Targets 2011, 12:1925-1956. 10.2174/138945011798184155, 21158707.
80. Khan R, Schmidt-Mende J, Karimi M, Gogvadze V, Hassan M, Ekström TJ, Zhivotovsky B, Hellström-Lindberg E. Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells. Exp Hematol 2008, 36:149-157. 10.1016/j.exphem.2007.10.002, 18206726.
81. Ruiz-Magaña MJ, Rodríguez-Vargas JM, Morales JC, Saldivia MA, Schulze-Osthoff K, Ruiz-Ruiz C. The DNA methyltransferase inhibitors zebularine and decitabine induce mitochondria-mediated apoptosis and DNA damage in p53 mutant leukemic T cells. Int J Cancer 2012, 130:1195-1207. 10.1002/ijc.26107, 21455989.
82. D'Alessio AC, Szyf M. Epigenetic tête-à-tête: the bilateral relationship between chromatin modifications and DNA methylation. Biochem Cell Biol 2006, 84:463-476. 10.1139/o06-090, 16936820.
83. Nguyen CT, Weisenberger DJ, Velicescu M, Gonzales FA, Lin JC, Liang G, Jones PA. Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2′-deoxycytidine. Cancer Res 2002, 62:6456-6461.
84. Lin JC, Jeong S, Liang G, Takai D, Fatemi M, Tsai YC, Egger G, Gal-Yam EN, Jones PA. Role of nucleosomal occupancy in the epigenetic silencing of the MLH1 CpG island. Cancer Cell 2007, 12:432-444. 10.1016/j.ccr.2007.10.014, 17996647.
85. Komashko VM, Farnham PJ. 5-azacytidine treatment reorganizes genomic histone modification patterns. Epigenetics 2010, 5:229-240.
86. Si J, Boumber YA, Shu J, Qin T, Ahmed S, He R, Jelinek J, Issa JP. Chromatin remodeling is required for gene reactivation after decitabine-mediated DNA hypomethylation. Cancer Res 2010, 70:6968-6977. 10.1158/0008-5472.CAN-09-4474, 2932851, 20713525.
87. Csoka AB, Szyf M. Epigenetic side-effects of common pharmaceuticals: a potential new field in medicine and pharmacology. Med Hypotheses 2009, 73:770-780. 10.1016/j.mehy.2008.10.039, 19501473.
88. Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, Dausman J, Gray JW, Leonhardt H, Jaenisch R. Induction of tumors in mice by genomic hypomethylation. Science 2003, 300:489-492. 10.1126/science.1083558, 12702876.
89. Holliday R, Pugh JE. DNA modification mechanisms and gene activity during development. Science 1975, 187:226-232. 10.1126/science.1111098, 1111098.
90. Bestor TH, Tycko B. Creation of genomic methylation patterns. Nat Genet 1996, 12:363-367. 10.1038/ng0496-363, 8630488.
91. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 2002, 21:5400-5413. 10.1038/sj.onc.1205651, 12154403.
92. Vera E, Canela A, Fraga MF, Esteller M, Blasco MA. Epigenetic regulation of telomeres in human cancer. Oncogene 2008, 27:6817-6833. 10.1038/onc.2008.289, 18762811.
93. Feltus FA, Lee EK, Costello JF, Plass C, Vertino PM. DNA motifs associated with aberrant CpG island methylation. Genomics 2006, 87:5728-5729.
94. Kang MI, Rhyu MG, Kim YH, Jung YC, Hong SJ, Cho CS, Kim HS. The length of CpG islands is associated with the distribution of Alu and L1 retroelements. Genomics 2006, 87:580-590. 10.1016/j.ygeno.2006.01.002, 16488573.
95. Deininger PL, Batzer MA. Alu repeats and human disease. Mol Genet Metab 1999, 67:183-193. 10.1006/mgme.1999.2864, 10381326.
96. Hagemann S, Heil O, Lyko F, Brueckner B. 5-azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines. PLoS One 2011, 6:e17388. 10.1371/journal.pone.0017388, 3049766, 21408221.
97. Tárnok A. Cytomics for discovering drugs. Cytometry A 2010, 77:1-2.
98. Dostie J, Richmond TA, Arnaout RR, Selzer RA, Lee WL, Honan TA, Rubio ED, Krumm A, Lamb J, Nusbaum C, Green RD, Dekker J. Chromosome conformation capture carbon copy (5C): a massively parallel solution for mapping interactions between genomic elements. Genome Res 2006, 16:1299-1309. 10.1101/gr.5571506, 1581439, 16954542.
99. Lieberman-Aiden E, van Berkum NL, Williams L, Imakaev M, Ragoczy T, Telling A, Amit I, Lajoie BR, Sabo PJ, Dorschner MO, Sandstrom R, Bernstein B, Bender MA, Groudine M, Gnirke A, Stamatoyannopoulos J, Mirny LA, Lander ES, Dekker J. Comprehensive mapping of long-range interactions reveals folding principles of the human genome. Science 2009, 326:289-293. 10.1126/science.1181369, 2858594, 19815776.
100. Fullwood MJ, Fullwood MJ, Liu MH, Pan YF, Liu J, Xu H, Mohamed YB, Orlov YL, Velkov S, Ho A, Mei PH, Chew EG, Huang PY, Welboren WJ, Han Y, Ooi HS, Ariyaratne PN, Vega VB, Luo Y, Tan PY, Choy PY, Wansa KD, Zhao B, Lim KS, Leow SC, Yow JS, Joseph R, Li H, Desai KV, Thomsen JS, et al. An oestrogen-receptor-a-bound human chromatin interactome. Nature 2009, 462:58-64. 10.1038/nature08497, 2774924, 19890323.
101. Goren A, Ozsolak F, Shoresh N, Ku M, Adli M, Hart C, Gymrek M, Zuk O, Regev A, Milos PM, Bernstein BE. Chromatin profiling by directly sequencing small quantities of immunoprecipitated DNA. Nat Methods 2010, 7:47-49. 10.1038/nmeth.1404, 2862482, 19946276.